Any claim that spending on the PBS is stagnant belies $3.3 billion in topline growth, representing the program's single biggest year-on-year financial expansion in its 75-year history, $7 billion in new listings over 18 months, Budget rules and the impact of the industry's agreements with the federal government.
Far from 'stagnating', the PBS has delivered record growth as it rapidly approaches $20 billion
May 10, 2023 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech